Weight Loss Drugs Market Size is valued at USD 26.3 billion in 2023 and is predicted to reach USD 108.9 billion by the year 2031 at a 19.7% CAGR during the forecast period for 2024-2031.
The weight loss drugs market is witnessing significant growth due to the global rise in obesity rates and related health concerns. With awareness of the health risks especially associated with obesity, there's a growing demand for effective weight management solutions. These drugs work by suppressing appetite, reducing fat absorption, or increasing metabolism. Factors such as unhealthy dietary habits and genetic predispositions contribute to the growing obesity epidemic, further fueling the market's expansion.
Moreover, advancements in drug development and increased research in obesity treatment drive innovation in this market. However, challenges such as safety concerns, side effects, and limited long-term efficacy of weight loss drugs persist. Regulatory hurdles and stringent approval processes also impact market growth. Despite these challenges, the weight loss drugs market is estimated to continue growing as the demand for effective weight management solutions remains strong.
The COVID-19 has had a significant impact on the weight loss drugs market. Initially, the market experienced disruptions due to lockdowns, restrictions on movement, and reduced healthcare facility access, which led to decreased patient visits and prescriptions for weight management drugs as healthcare resources were diverted towards managing the pandemic. It increased the risk of the obese population, leading to COVID-19 mortality, which increased the demand for weight loss drugs during COVID-19. However, increased awareness about healthy lifestyles and weight concerns during the pandemic is expected to maintain the demand for anti-obesity drugs even post-pandemic period.
The weight loss drugs market is segmented by product type, application, and distribution channel. The market is divided into prescription and over-the-counter. By application, the market segments include appetite suppression, fat blocking, and others. Finally, by distribution channel, the segmentation includes hospital pharmacy, retail pharmacy, and online pharmacy.
Appetite suppressants hold significant market share in the weight loss drugs market due to their established history, efficacy, wide availability, and cost-effectiveness. Drugs like Phentermine have been trusted for decades, providing effective short-term weight loss by reducing appetite. Their affordability, including generic options, makes them accessible to a broader population. Appetite suppressants are often prescribed as part of comprehensive weight loss plans, supporting dietary adherence. Regulatory approvals and inclusion in clinical guidelines bolster their credibility. Patient preferences for rapid, noticeable effects and ease of use further drive their popularity. Despite the emergence of newer drugs like GLP-1 receptor agonists, appetite suppressants remain essential for initiating weight loss and supporting behavioral changes in weight management strategies.
The online pharmacy segment in the weight loss drugs market involves the distribution of weight loss medications through digital platforms. Online pharmacies offer convenience, accessibility, and discretion for individuals seeking weight loss treatments. Customers can consult with healthcare professionals remotely, obtain prescriptions, and purchase medications online, often at lower prices compared to traditional pharmacies. These platforms provide a wide range of weight loss drugs, including prescription and over-the-counter options. However, challenges such as the risk of counterfeit drugs, regulatory compliance, and the need for accurate medical assessments persist. Despite challenges, the online pharmacy segment continues to grow due to its convenience and increasing consumer preference for digital healthcare solutions.
The North American weight loss drugs market is expected to have the highest market share in terms of revenue in the near future. It can be attributed to the high demand for weight loss drugs due to the youth's fitness trends and health awareness. Besides, the rise in cases of lifestyle-related diseases has triggered the need for weight loss drugs in the common population. Moreover, North America is a rapidly growing market for weight loss drugs attributed to the popularity of dietary supplements and weight loss drugs. Europe is seen to grow at a significant rate in the global Weight Loss Drugs Market due to growing concerns for weight loss drugs attributed to the growing prevalence of obesity: rapid industrialization, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 26.3 Bn |
|
Revenue Forecast In 2031 |
USD 108.9 Bn |
|
Growth Rate CAGR |
CAGR of 19.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, By Application and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novo Nordisk A/S, Eli Lilly & Co., Amgen Inc., Pfizer Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, and Sandoz International GmbH. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Weight Loss Drugs Market Snapshot
Chapter 4. Global Weight Loss Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis
5.1. by Drug Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Type:
5.2.1. Prescription
5.2.2. Over-the-counter
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Appetite Suppression
6.2.2. Fat Blocking
6.2.3. Others
Chapter 7. Weight Loss Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
7.1.2. North America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.1.3. North America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
7.2.2. Europe Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.2.3. Europe Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
7.3.2. Asia-Pacific Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.3.3. Asia Pacific Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
7.4.2. Latin America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.4.3. Latin America Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
7.5.2. Middle East & Africa Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.5.3. Middle East & Africa Weight Loss Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novo Nordisk A/S
8.2.2. Eli Lilly & Co.
8.2.3. Amgen Inc.
8.2.4. Pfizer Inc.
8.2.5. Viking Therapeutics Inc.
8.2.6. Structure Therapeutics Inc.
8.2.7. F. Hoffmann-La Roche Ltd
8.2.8. Teva Pharmaceutical Industries Ltd
8.2.9. GlaxoSmithKline plc
8.2.10. Sandoz International GmbH
8.2.11. Other Prominent Players
Weight Loss Drugs Market- By Drug Type
Weight Loss Drugs Market- By Application
Weight Loss Drugs Market- By Distribution Channel
Weight Loss Drugs Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
